Chapter 7


28. Gras L et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. Journal of Acquired Immune Deficiency Syndromes, 2007, 45:183–192.


70. Fang C-T et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. Journal of Infectious Diseases, 2009, 190:879–885.


120. Duncombe C et al. Treatment 2.0: catalysing the next phase of treatment, care and support Current Opinion in HIV and AIDS, 2013, 8:4–11.


174. 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, 30 June – 3 July 2013, Kuala Lumpur, Malaysia.


222. Arasteh K et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Therapy, 2009, 14:859–864.


